» Articles » PMID: 26807589

A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection

Overview
Journal PLoS One
Date 2016 Jan 26
PMID 26807589
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In Thailand, the combined generic anti-retroviral drug stavudine/lamivudine/nevirapine (d4T/3TC/NVP) has been used to treat human immunodeficiency virus (HIV)-infected individuals since 2001. Due to relatively frequent adverse effects, d4T gradually has been replaced with tenofovir disoproxil fumarate (TDF). Although the frequency of adverse drug effects with TDF is lower than that with d4T, TDF is known to induce kidney dysfunction, especially in the proximal tubules. It has been reported that renal tubular transporters, including members of the multi-drug resistant (MDR) protein family, are implicated in tenofovir extrusion and may, therefore, confer susceptibility to TDF-induced kidney tubular dysfunction (KTD). We have explored the association between KTD and polymorphisms in genes that encode adenosine triphosphate-binding cassette (ABC)-type MDRs.

Methods: HIV-infected patients receiving TDF-containing antiretroviral regimens for at least one year were enrolled in the study. The levels of beta2-microglobulin in urine and creatinine (Cr) were measured. Three single-nucleotide polymorphisms, ABCC2 C-24T (rs717620), ABCC2 G1429A (rs2273697), and ABCC4 T4976C (rs1059751), were analyzed using TaqMan SNP genotyping assays.

Results: A total of 273 HIV-infected patients were recruited. The median number of years of TDF treatment was 5.04 with interquartile range (IQR) of 3.9-6.7. Despite the length of treatment with TDF, 98.5% patients maintained an estimated glomerular filtration rate (eGFR) of >60 mL/min as calculated by the CKD-EPI formula. Fifty-four patients (19.8%) showed beta2-microglobulinuria (median 2636 μg/g Cr with IQR of 1519-13197 μg/g Cr). The allele frequency of ABCC4 T4976C among those 54 patients was 0.602, compared to 0.475 among the 219 remaining patients (p = 0.018).

Conclusions: Approximately 20% of HIV-infected patients receiving TDF showed beta2-microglobulinuria. The C allele at position 4976 of the ABCC4 gene was associated with beta2-microglobulinuria in this population. This polymorphism may help to identify patients at greater risk for developing TDF-associated KTD.

Citing Articles

Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis.

Yazie T, Shiferaw W, Gebeyehu A, Teshome A, Addisu Z, Belete A PLoS One. 2025; 20(2):e0318068.

PMID: 39913460 PMC: 11801554. DOI: 10.1371/journal.pone.0318068.


Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans.

Mateza S, Bradford Y, Maartens G, Sokhela S, Chandiwana N, Venter W Pharmacogenet Genomics. 2023; 33(5):91-100.

PMID: 37099271 PMC: 10234323. DOI: 10.1097/FPC.0000000000000491.


Updates on HIV and Kidney Disease.

Cervantes C, Atta M Curr HIV/AIDS Rep. 2023; 20(2):100-110.

PMID: 36695948 DOI: 10.1007/s11904-023-00645-1.


Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate.

Phuphuakrat A, Pasomsub E, Chantratita W, Mahasirimongkol S, Disthabanchong S, Sungkanuparph S J Int Assoc Provid AIDS Care. 2022; 21:23259582221134751.

PMID: 36314476 PMC: 9623366. DOI: 10.1177/23259582221134751.


Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV.

Zondo N, Sobia P, Sivro A, Ngcapu S, Ramsuran V, Archary D Front Genet. 2022; 13:940661.

PMID: 36246609 PMC: 9557974. DOI: 10.3389/fgene.2022.940661.


References
1.
Rodriguez-Novoa S, Labarga P, DAvolio A, Barreiro P, Albalate M, Vispo E . Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010; 24(7):1064-6. DOI: 10.1097/QAD.0b013e32833202e2. View

2.
Izzedine H, Harris M, Perazella M . The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009; 5(10):563-73. DOI: 10.1038/nrneph.2009.142. View

3.
Zimmermann A, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G . Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2005; 42(2):283-90. DOI: 10.1086/499048. View

4.
Nelson M, Katlama C, Montaner J, Cooper D, Gazzard B, Clotet B . The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007; 21(10):1273-81. DOI: 10.1097/QAD.0b013e3280b07b33. View

5.
Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L . Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2009; 53(1):62-9. DOI: 10.1097/QAI.0b013e3181be6be2. View